Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fondaparinux Sodium Clear all
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

NCT00464087
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Bridgeport, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 20, 2026, 10:09 PM EDT
Terminated Phase 3 Interventional Results available

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683
View directory record Official record
Conditions
Cancer, Thromboembolism
Interventions
Arixtra alone, Arixtra + filter
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Results available

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

NCT00412464
View directory record Official record
Conditions
Thrombosis, Heparin-induced Thrombocytopenia
Interventions
Fondaparinux
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 20, 2026, 10:09 PM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

NCT00060554
View directory record Official record
Conditions
Myocardial Infarction, Coronary Disease
Interventions
fondaparinux sodium, heparin, percutaneous coronary intervention (PCI)
Drug · Procedure
Lead sponsor
Schering-Plough
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Ocala, Florida • Chicago, Illinois • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

NCT01895777
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate, standard of care
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 20, 2026, 10:09 PM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 20, 2026, 10:09 PM EDT
Not listed No phase listed Observational

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

NCT00424281
View directory record Official record
Conditions
ICU Patients 18 Years or Older.
Interventions
Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Sep 20, 2026, 10:09 PM EDT
Withdrawn Phase 1 Interventional

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NCT00659399
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Fondaparinux
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 20, 2026, 10:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

NCT00346879
View directory record Official record
Conditions
Morbid Obesity
Interventions
fondaparinux
Drug
Lead sponsor
Indiana University
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 2 Interventional

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

NCT00436787
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux Sodium
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2008 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 1 Interventional

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

NCT01121770
View directory record Official record
Conditions
Renal Insufficiency
Interventions
fondaparinux sodium injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Not applicable Interventional

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

NCT00413504
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 2 Interventional

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Early Phase 1 Interventional

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

NCT00894283
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 20, 2026, 10:09 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

NCT00539942
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 4 Interventional Results available

Fondaparinux in Critically Ill Patients With Renal Failure

NCT01467583
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Fondaparinux
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 20, 2026, 10:09 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

NCT00909064
View directory record Official record
Conditions
Total Knee Replacement
Interventions
Fondaparinux Sodium (Arixtra)
Drug
Lead sponsor
Paul Di Cesare,MD
Other
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 20, 2026, 10:09 PM EDT